Tirzepatide Weight Loss

Tirzepatide is a second-generation weight loss medication that targets two receptors instead of one. The GLP-1 pathway suppresses appetite while the GIP pathway improves insulin sensitivity and enhances fat burning. Clinical trials show up to 22.5% body weight loss, significantly more than single-agonist medications.

Many patients who experienced nausea or difficulty eating enough on semaglutide find tirzepatide easier to tolerate. The GIP component helps buffer common GLP-1 side effects while delivering more aggressive weight loss results.

Our tirzepatide is sourced from FDA-registered compounding pharmacies with rigorous quality controls: weekly potency batch testing, 3% variance tolerance (well below the 10% industry standard), and sterility testing before every batch is dispensed.

Meet with our medical team to review your health history, metabolic markers, and weight loss goals. We determine if tirzepatide is the right fit, especially if you have insulin resistance or metabolic syndrome.

Begin with a low dose and gradually increase over 4 to 8 weeks. We train you on self-injection (upper arm, stomach, or thigh) and monitor your response at every step.

Most patients notice reduced hunger and improved energy within 2 to 4 weeks. The GIP pathway enhances fat metabolism while GLP-1 curbs appetite, so weight drops faster than with single-agonist medications.

Regular follow-ups to track progress, adjust dosing, and fine-tune your protocol. Our goal is sustainable weight loss of up to 22.5% body weight over 6 to 12 months.

Tirzepatide is a dual-action GLP-1 and GIP receptor agonist. It activates two gut-hormone pathways at once: GLP-1 curbs appetite and slows digestion, while GIP improves fat metabolism and insulin sensitivity. This dual mechanism is why tirzepatide delivers greater weight loss than single-agonist medications like semaglutide.

Clinical trials showed average weight loss of up to 22.5% of body weight over 72 weeks at the highest dose. Individual results vary based on starting weight, adherence, and lifestyle factors. Our physician-supervised program is designed to maximize your results.

Semaglutide targets one hormone pathway (GLP-1). Tirzepatide targets two (GLP-1 + GIP), which is why clinical data shows greater average weight loss: up to 22.5% vs. up to 15%. Both are weekly injections. Our physicians will recommend the best option for your health profile during your consultation.

The most common side effects are mild nausea, constipation, and occasional diarrhea, usually during the first few weeks as your body adjusts. We start at a low dose and increase gradually to minimize these effects. Most patients find side effects manageable and temporary.

Same active ingredient. Mounjaro is FDA-approved for type 2 diabetes; Zepbound is approved specifically for weight management. Our compounded tirzepatide uses the same base compound, sourced from FDA-registered pharmacies with strict quality controls.

A free consultation at our Brandon clinic. We review your health history, discuss your goals, and determine if tirzepatide is the right fit for you. No referrals needed, no long waits.

Yes. Our clinic is conveniently located at 1767 S Kings Ave in Brandon, FL. We serve patients from Valrico, FishHawk, Bloomingdale, Seffner, Riverview, and the greater Tampa Bay area.